NEW YORK, Sept. 13, 2024 /PRNewswire/ -- Report on how AI
is driving market transformation- The global menstrual drugs market
size is estimated to grow by USD 3.61
billion from 2024-2028, according to Technavio. The market
is estimated to grow at a CAGR of 7.75% during the forecast period.
Growing emphasis on educating women about menstrual
health is driving market growth, with a trend
towards increase in popularity of drug therapy.
However, increasing popularity of non-drug alternatives poses
a challenge. Key market players include AbbVie Inc., Adorefem,
Bayer AG, Cipla Inc., Dr Reddys Laboratories Ltd., GlaxoSmithKline
Plc, Haleon Plc, Himalaya Wellness Co., Johnson and Johnson
Services Inc., Leeford Healthcare Ltd., Mallinckrodt Plc, Maxwellia
Ltd., Perrigo Co. Plc, Pfizer Inc., Reckitt Benckiser Group Plc,
Sanofi SA, SteriMax Inc., Sumitomo Chemical Co. Ltd., Teva
Pharmaceutical Industries Ltd., Walgreens Boots Alliance Inc., and
Zydus Lifesciences Ltd..
Key insights into market evolution with
AI-powered analysis. Explore trends, segmentation, and growth
drivers-View the snapshot of this report
Menstrual Drugs
Market Scope
|
Report
Coverage
|
Details
|
Base year
|
2023
|
Historic
period
|
2018 - 2022
|
Forecast
period
|
2024-2028
|
Growth momentum &
CAGR
|
Accelerate at a CAGR of
7.75%
|
Market growth
2024-2028
|
USD 3619.4
million
|
Market
structure
|
Fragmented
|
YoY growth 2022-2023
(%)
|
7.31
|
Regional
analysis
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Performing market
contribution
|
North America at
33%
|
Key
countries
|
US, China, Germany,
India, and UK
|
Key companies
profiled
|
AbbVie Inc., Adorefem,
Bayer AG, Cipla Inc., Dr Reddys Laboratories Ltd., GlaxoSmithKline
Plc, Haleon Plc, Himalaya Wellness Co., Johnson and Johnson
Services Inc., Leeford Healthcare Ltd., Mallinckrodt Plc, Maxwellia
Ltd., Perrigo Co. Plc, Pfizer Inc., Reckitt Benckiser Group Plc,
Sanofi SA, SteriMax Inc., Sumitomo Chemical Co. Ltd., Teva
Pharmaceutical Industries Ltd., Walgreens Boots Alliance Inc., and
Zydus Lifesciences Ltd.
|
Market Driver
The menstrual drugs market has experienced significant growth
due to advancements in medical research and technology.
Pharmaceutical companies and research institutions have invested in
creating new drug formulations and treatment methods for menstrual
conditions. These innovations offer improved efficacy, safety, and
patient convenience, making drug-based interventions increasingly
popular. For instance, Pfizer Inc. And Myovant Sciences' Myfembree,
a once-daily treatment for endometriosis-related pelvic pain,
received US FDA approval in August
2022. This approval introduces a new treatment option for
women suffering from endometriosis, addressing the hormonal
imbalance causing debilitating pelvic pain. This development is
expected to boost the global menstrual drugs market's
expansion.
The Menstrual Drugs Market is experiencing significant growth
due to the rising prevalence of Primary Dysmenorrhea and Secondary
Dysmenorrhea. Treatment types include Medication, Therapy, Surgery,
and Diagnosis using tools like Ultrasound, Laparoscopy, and CT
scan. Prescription Medications come in various forms such as Oral,
Parenteral, Implants, and Over the Counter. Hospitals, Specialty
Clinics, Homecare, and Pharmacies (Hospital, Retail, Online) are
key sales channels. Dysmenorrhea affects millions, with heavy
patient epidemiology. Pipeline Analysis includes Gene Therapy,
Digital Health, and Telemedicine. Side Effects from Combined Oral
Contraceptives are a concern. Healthcare Infrastructure focuses on
managing Pelvic Pain from Endometriosis and Heavy Menstrual
Bleeding. Clinical Trials are in Phase 2. Treatment Duration and
Administration methods (Analgesics, Oral, Injectable, Topical)
vary. Livia Portable Device is an alternative treatment
option.
Request Sample of our comprehensive
report now to stay ahead in the AI-driven market evolution!
Market Challenges
- The menstrual drugs market has experienced challenges due to
the rising preference for non-drug alternatives among consumers.
These alternatives, which include herbal supplements, dietary
changes, exercise, acupuncture, yoga, and mindfulness practices,
have gained popularity due to concerns about potential side effects
and long-term implications of conventional medications. The ease of
access to information about non-drug alternatives through online
platforms and social media has influenced consumer choices.
Pharmaceutical companies producing menstrual drugs face stiff
competition from natural health products and dietary supplements,
leading them to reevaluate marketing strategies, product
development, and research priorities. Regulatory bodies are
scrutinizing the safety and efficacy of non-drug alternatives,
increasing consumer awareness about risks and benefits. As a
result, some individuals opt for non-drug alternatives, negatively
impacting the demand for menstrual drugs and hindering market
growth.
- The Menstrual Drugs Market encompasses various segments,
including implants, hospitals, specialty clinics, homecare,
hospital pharmacies, retail pharmacies, and online pharmacies. The
market caters to the needs of women suffering from conditions like
dysmenorrhea, endometriosis, pelvic pain, and heavy menstrual
bleeding. The pipeline analysis includes gene therapy, digital
health, and telemedicine. Challenges include side effects,
healthcare infrastructure, and treatment duration. Combined oral
contraceptives, hormonal therapy, and analgesics like ibuprofen and
naproxen sodium are common treatments. Medical reimbursement,
menstrual hygiene, and menstrual cramps are essential aspects of
the market. Alternative treatments like Livia Portable Device and
SmartWave Technology are gaining popularity. Prostaglandins and
non-steroidal anti-inflammatory drugs are administered through
oral, injectable, and topical methods. The market includes hospital
pharmacies, retail pharmacies, online pharmacies, and drug stores.
Clinical trials are in Phase 2 for new treatments. Menstrual
Hygiene Day highlights the importance of addressing menstrual
health issues.
Discover how AI is revolutionizing market
trends-Get your access now!
Segment Overview
This menstrual drugs market report extensively covers market
segmentation by
- Type
- 1.1 Hormonal treatments
- 1.2 Pain relief medications
- 1.3 PMS and PMDD medications
- 1.4 Menstrual regulation drugs
- 1.5 Endometriosis treatments
- Route Of Administration
- 2.1 Oral medications
- 2.2 Injectables
- 2.3 Topical applications
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 Hormonal treatments- The Menstrual Drugs Market
refers to the business sector that produces and sells medications
used to manage menstrual cycles. These drugs include oral
contraceptives, hormone replacement therapy, and menstrual pain
relievers. The market size is significant due to the large global
population of menstruating women. Companies in this industry focus
on research and development to provide effective and safe solutions
for menstrual health management. Competition is strong, with major
players investing in marketing and distribution strategies to reach
consumers. Market growth is driven by increasing awareness and
acceptance of menstrual health products, as well as advancements in
technology and research.
Download a Sample of our
comprehensive report today to discover how AI-driven innovations
are reshaping competitive dynamics
Research Analysis
Menstrual cramps, also known as dysmenorrhea, can cause
significant pelvic pain and discomfort during menstruation. Primary
dysmenorrhea is the most common form, occurring in the absence of
underlying conditions, while secondary dysmenorrhea is caused by
conditions such as endometriosis or pelvic inflammatory disease.
Treatment options for menstrual cramps include various types of
medication, therapy, and surgery. Medications for menstrual cramps
include prostaglandins, non-steroidal anti-inflammatory drugs
(NSAIDs) like ibuprofen and naproxen sodium, and hormonal therapy.
These can be administered orally, injectable, or topically.
Ultrasound, laparoscopy, and CT scan may be used for diagnosis,
while clinical trials are ongoing in Phase 2 for new treatment
options. Treatment duration varies depending on the individual and
the severity of symptoms. Analgesics are commonly used to manage
pain, and over-the-counter medicines are often the first line of
treatment for menstrual cramps. Heavy menstrual bleeding may also
require specific treatment. It is important to consult a healthcare
professional for proper diagnosis and treatment.
Market Research Overview
Menstrual drugs market refers to the segment of pharmaceuticals
dedicated to treating various menstrual disorders, including
Primary and Secondary Dysmenorrhea. Primary Dysmenorrhea is
characterized by painful menstrual cramps, while Secondary
Dysmenorrhea is caused by underlying conditions like Endometriosis
or Pelvic Inflammatory Disease. Treatment types range from
Medication, Therapy, Surgery, and Diagnosis. Ultrasound,
Laparoscopy, and CT scan are common diagnostic methods. Mode of
Prescription includes Over the Counter (OTC) and Prescription. Oral
and Parenteral are common administration types, with Implants also
available. Hospitals, Specialty Clinics, Homecare, Hospital
Pharmacy, Retail Pharmacy, and Online Pharmacy are key distribution
channels. Dysmenorrhea affects millions worldwide, with an
increasing pipeline analysis focusing on Gene Therapy and Digital
Health solutions like Telemedicine. Combined Oral Contraceptives,
Prostaglandins, Non-steroidal anti-inflammatory drugs (NSAIDs) like
Ibuprofen and Naproxen sodium, and Hormonal therapy are common
medications. Side effects and Medical Reimbursement are crucial
considerations. Menstrual Hygiene is essential, with Menstrual
Hygiene Day promoting awareness. Alternative treatments include the
Livia Portable Device and SmartWave Technology. Menstrual cramps
affect millions, driving the Treatment market.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Type
-
- Hormonal Treatments
- Pain Relief Medications
- PMS And PMDD Medications
- Menstrual Regulation Drugs
- Endometriosis Treatments
- Route Of Administration
-
- Oral Medications
- Injectables
- Topical Applications
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/menstrual-drugs-market-to-grow-by-usd-3-61-billion-2024-2028-driven-by-increased-focus-on-womens-menstrual-health-education-ai-powered-report--technavio-302246549.html
SOURCE Technavio